A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants

Inclusion criteria

• Body mass index (BMI) between 18.0 and 32.0 kilogram per square metre (kg/m^2), inclusive, and a total body weight greater than or equal to 50 kilograms (kg)
• Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception
• Able to comprehend and willing to sign an informed consent form (ICF) and to abide by the study restrictions
• Able to swallow tablets

Exclusion criteria

• History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator (or designee)
• History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs
• QTcF interval >430 ms for males and >440 ms for females or QRS >120 ms
• A history of additional risk factors for torsade de pointes (eg, heart failure, hypokalemia, or family history of long QT syndrome)
• Positive serology test results for hepatitis B panel and hepatitis C antibody and/or reactive human immunodeficiency virus 1/2 test
• Administration of a coronavirus disease 2019 (COVID-19) vaccine in the past 14 days prior to dosing
• Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to dosing, unless deemed acceptable by the investigator (or designee)
• Use or intend to use any prescription medications/products within 14 days prior to dosing, unless deemed acceptable by the investigator (or designee)
• Use or intend to use slow-release medications/products considered to still be active within 14 days prior to check-in, unless deemed acceptable by the investigator (or designee)
• Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations within 7 days prior to check-in, unless deemed acceptable by the investigator (or designee)
• Use or intend to use any medications that may increase QT interval within 14 days prior to check-in
• Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days prior to dosing
• Have previously completed or withdrawn from this study or any other study investigating brensocatib, and have previously received brensocatib
• Alcohol consumption of >14 units per week for males and >7 units for females. One unit of alcohol equals 12 ounce (oz) (360 milliliter [mL]) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL) wine
• Consumption of caffeine-containing products within 48 hours prior to check-in, unless deemed acceptable by the investigator (or designee)
• History of chemical abuse, illicit substance, or marijuana use within 1 year prior to check-in
• Use of tobacco- or nicotine-containing products within 3 months prior to check-in
• Receipt of blood products within 2 months prior to check-in
• Donation of blood from 3 months prior to screening, plasma from 2 weeks prior to screening, or platelets from 6 weeks prior to screening
• Poor peripheral venous access